Table of Contents
1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Executive Summary
3. Global Vocal Biomarker Market Insights
3.1. Industry Value Chain Analysis
3.2. DROC Analysis
3.2.1. Growth Drivers
3.2.1.1. Increasing Prevalence of Parkinson's Disease and Other Diseases
3.2.1.2. Increasing Need for Minimally Invasive Treatments to Diagnose Different Illnesses
3.2.1.3. Rising Incidence of Cardiovascular and Mental Disorders
3.2.2. Restraints
3.2.2.1. Errors and Inaccuracy of Vocal Biomarkers
3.2.2.2. High Cost of Techniques
3.2.3. Opportunities
3.2.3.1. Increasing The Research Study of Vocal Biomarkers
3.2.3.2. Successful Completion of Clinical Investigations of Voice Biomarker
3.2.4. Challenges
3.3. Technology Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter's Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
4. Global Vocal Biomarker Market Overview
4.1. Market Size & Forecast by Value, 2019-2029
4.1.1. By Value (USD Billion)
4.2. Market Share & Forecast
4.2.1. By Type
4.2.1.1. Frequency
4.2.1.2. Amplitude
4.2.1.3. Error Rate
4.2.1.4. Vocal Rise or Fall Time
4.2.1.5. Phonation Time
4.2.1.6. Voice Tremor
4.2.1.7. Pitch
4.2.2. By Indication
4.2.2.1. Depression
4.2.2.2. Attention Deficit
4.2.2.3. Disruptive Behavior Disorders
4.2.2.4. Others
4.2.3. By Neurological Disorders
4.2.3.1. Parkinson's Disease
4.2.3.2. Alzheimer's Disease
4.2.3.3. Huntington's Disease
4.2.3.4. Respiratory and Cardiovascular Disorders
4.2.3.5. Traumatic Brain Injury
4.2.4. By End User
4.2.4.1. Hospitals and Clinics
4.2.4.2. Academic and Research
4.2.4.3. Others
4.2.5. By Region
4.2.5.1. North America
4.2.5.2. Europe
4.2.5.3. Asia Pacific
4.2.5.4. Latin America
4.2.5.5. Middle East and Africa
5. North America Vocal Biomarker Market
5.1. Market Size & Forecast by Value, 2019-2029
5.1.1. By Value (USD Billion)
5.2. Market Share & Forecast
5.2.1. By Type
5.2.2. By Indication
5.2.3. By Neurological Disorders
5.2.4. By End User
5.2.5. By Country
5.2.5.1. US
5.2.5.1.1. By Type
5.2.5.1.2. By Indication
5.2.5.1.3. By Neurological Disorders
5.2.5.1.4. By End User
5.2.5.2. Canada
5.2.5.2.1. By Type
5.2.5.2.2. By Indication
5.2.5.2.3. By Neurological Disorders
5.2.5.2.4. By End User
6. Europe Vocal Biomarker Market
6.1. Market Size & Forecast by Value, 2019-2029
6.1.1. By Value (USD Billion)
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Indication
6.2.3. By Neurological Disorders
6.2.4. By End User
6.2.5. By Country
6.2.5.1. Germany
6.2.5.1.1. By Type
6.2.5.1.2. By Indication
6.2.5.1.3. By Neurological Disorders
6.2.5.1.4. By End User
6.2.5.2. UK
6.2.5.2.1. By Type
6.2.5.2.2. By Indication
6.2.5.2.3. By Neurological Disorders
6.2.5.2.4. By End User
6.2.5.3. Italy
6.2.5.3.1. By Type
6.2.5.3.2. By Indication
6.2.5.3.3. By Neurological Disorders
6.2.5.3.4. By End User
6.2.5.4. France
6.2.5.4.1. By Type
6.2.5.4.2. By Indication
6.2.5.4.3. By Neurological Disorders
6.2.5.4.4. By End User
6.2.5.5. Spain
6.2.5.5.1. By Type
6.2.5.5.2. By Indication
6.2.5.5.3. By Neurological Disorders
6.2.5.5.4. By End User
6.2.5.6. The Netherlands
6.2.5.6.1. By Type
6.2.5.6.2. By Indication
6.2.5.6.3. By Neurological Disorders
6.2.5.6.4. By End User
6.2.5.7. Rest of Europe
6.2.5.7.1. By Type
6.2.5.7.2. By Indication
6.2.5.7.3. By Neurological Disorders
6.2.5.7.4. By End User
7. Asia-Pacific Vocal Biomarker Market
7.1. Market Size & Forecast by Value, 2019-2029
7.1.1. By Value (USD Billion)
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Indication
7.2.3. By Neurological Disorders
7.2.4. By End User
7.2.5. By Country
7.2.5.1. China
7.2.5.1.1. By Type
7.2.5.1.2. By Indication
7.2.5.1.3. By Neurological Disorders
7.2.5.1.4. By End User
7.2.5.2. India
7.2.5.2.1. By Type
7.2.5.2.2. By Indication
7.2.5.2.3. By Neurological Disorders
7.2.5.2.4. By End User
7.2.5.3. Japan
7.2.5.3.1. By Type
7.2.5.3.2. By Indication
7.2.5.3.3. By Neurological Disorders
7.2.5.3.4. By End User
7.2.5.4. South Korea
7.2.5.4.1. By Type
7.2.5.4.2. By Indication
7.2.5.4.3. By Neurological Disorders
7.2.5.4.4. By End User
7.2.5.5. Australia & New Zealand
7.2.5.5.1. By Type
7.2.5.5.2. By Indication
7.2.5.5.3. By Neurological Disorders
7.2.5.5.4. By End User
7.2.5.6. Indonesia
7.2.5.6.1. By Type
7.2.5.6.2. By Indication
7.2.5.6.3. By Neurological Disorders
7.2.5.6.4. By End User
7.2.5.7. Malaysia
7.2.5.7.1. By Type
7.2.5.7.2. By Indication
7.2.5.7.3. By Neurological Disorders
7.2.5.7.4. By End User
7.2.5.8. Singapore
7.2.5.8.1. By Type
7.2.5.8.2. By Indication
7.2.5.8.3. By Neurological Disorders
7.2.5.8.4. By End User
7.2.5.9. Philippines
7.2.5.9.1. By Type
7.2.5.9.2. By Indication
7.2.5.9.3. By Neurological Disorders
7.2.5.9.4. By End User
7.2.5.10. Vietnam
7.2.5.10.1. By Type
7.2.5.10.2. By Indication
7.2.5.10.3. By Neurological Disorders
7.2.5.10.4. By End User
7.2.5.11. Rest of Asia Pacific
7.2.5.11.1. By Type
7.2.5.11.2. By Indication
7.2.5.11.3. By Neurological Disorders
7.2.5.11.4. By End User
8. Latin America Vocal Biomarker Market
8.1. Market Size & Forecast by Value, 2019-2029
8.1.1. By Value (USD Billion)
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Indication
8.2.3. By Neurological Disorders
8.2.4. By End User
8.2.5. By Country
8.2.5.1. Brazil
8.2.5.1.1. By Type
8.2.5.1.2. By Indication
8.2.5.1.3. By Neurological Disorders
8.2.5.1.4. By End User
8.2.5.2. Mexico
8.2.5.2.1. By Type
8.2.5.2.2. By Indication
8.2.5.2.3. By Neurological Disorders
8.2.5.2.4. By End User
8.2.5.3. Argentina
8.2.5.3.1. By Type
8.2.5.3.2. By Indication
8.2.5.3.3. By Neurological Disorders
8.2.5.3.4. By End User
8.2.5.4. Peru
8.2.5.4.1. By Type
8.2.5.4.2. By Indication
8.2.5.4.3. By Neurological Disorders
8.2.5.4.4. By End User
8.2.5.5. Colombia
8.2.5.5.1. By Type
8.2.5.5.2. By Indication
8.2.5.5.3. By Neurological Disorders
8.2.5.5.4. By End User
8.2.5.6. Rest of LATAM
8.2.5.6.1. By Type
8.2.5.6.2. By Indication
8.2.5.6.3. By Neurological Disorders
8.2.5.6.4. By End User
9. Middle East & Africa Vocal Biomarker Market
9.1. Market Size & Forecast by Value, 2019-2029
9.1.1. By Value (USD Billion)
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Indication
9.2.3. By Neurological Disorders
9.2.4. By End User
9.2.5. By Country
9.2.5.1. Saudi Arabia
9.2.5.1.1. By Type
9.2.5.1.2. By Indication
9.2.5.1.3. By Neurological Disorders
9.2.5.1.4. By End User
9.2.5.2. UAE
9.2.5.2.1. By Type
9.2.5.2.2. By Indication
9.2.5.2.3. By Neurological Disorders
9.2.5.2.4. By End User
9.2.5.3. Qatar
9.2.5.3.1. By Type
9.2.5.3.2. By Indication
9.2.5.3.3. By Neurological Disorders
9.2.5.3.4. By End User
9.2.5.4. Kuwait
9.2.5.4.1. By Type
9.2.5.4.2. By Indication
9.2.5.4.3. By Neurological Disorders
9.2.5.4.4. By End User
9.2.5.5. South Africa
9.2.5.5.1. By Type
9.2.5.5.2. By Indication
9.2.5.5.3. By Neurological Disorders
9.2.5.5.4. By End User
9.2.5.6. Nigeria
9.2.5.6.1. By Type
9.2.5.6.2. By Indication
9.2.5.6.3. By Neurological Disorders
9.2.5.6.4. By End User
9.2.5.7. Algeria
9.2.5.7.1. By Type
9.2.5.7.2. By Indication
9.2.5.7.3. By Neurological Disorders
9.2.5.7.4. By End User
9.2.5.8. Rest of MEA
9.2.5.8.1. By Type
9.2.5.8.2. By Indication
9.2.5.8.3. By Neurological Disorders
9.2.5.8.4. By End User
10. Competitive Landscape
10.1. List of Key Players and Their Offerings
10.2. Global Vocal Biomarker Company Market Share Analysis, 2022
10.3. Competitive Benchmarking, By Operating Parameters
10.4. Key Strategic Development (Mergers, Acquisitions, Partnerships, and others)
11. Impact of Covid-19 on Global Vocal Biomarker Market
12. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)
12.1. Sonde Health
12.2. Beyond Verbal
12.3. IBM Corporation
12.4. Cogito Corporation
12.5. Boston Technology Corporation
12.6. Microtest Health
12.7. Other Prominent Players
13. Key Strategic Recommendations
14. Research Methodology
14.1. Qualitative Research
14.1.1. Primary & Secondary Research
14.2. Quantitative Research
14.3. Market Breakdown & Data Triangulation
14.3.1. Secondary Research
14.3.2. Primary Research
14.4. Breakdown of Primary Research Respondents, By Region
14.5. Assumptions & Limitations